Document is current
Any future updates will be listed below
-
Authors
LoParo, Devon
Dunlop, Boadie W.
Nemeroff, Charles B.
Mayberg, Helen S.
Craighead, W. Edward
-
Funding
Funding for this research was provided by:
National Institute of Mental Health (R01 MH073719, P50-MH077083, R01-MH080880, UL1-RR025008, and M01-RR0039, R01 MH073719, P50-MH077083, R01-MH080880, UL1-RR025008, and M01-RR0039, R01 MH073719, P50-MH077083, R01-MH080880, UL1-RR025008, and M01-RR0039, R01 MH073719, P50-MH077083, R01-MH080880, UL1-RR025008, and M01-RR0039)
- License Information
-
More Information
Article History
Received: 14 May 2024
Accepted: 24 January 2025
First Online: 5 February 2025
Competing interests
: Dr. LoParo has no financial relationships with competing interests. Dr. Dunlop has received research support from Boehringer Ingelheim, Compass Pathways, NIMH, Otsuka, Sage, Usona Institute, and Takeda and has served as a consultant for Biohaven, Cerebral Therapeutics, Myriad Neuroscience, NRx Pharmaceuticals, Otsuka, and Sage. Dr. Nemeroff has served as a consultant for AbbVie, ANeuroTech (division of Anima BV), Signant Health, Magstim, Inc., Intra-Cellular Therapies, Inc., EMA Wellness, Sage, Silo Pharma, EmbarcNeuro, Engrail Therapeutics, Pasithea Therapeutic Corp., GoodCap Pharmaceuticals, Inc., Senseye, Clexio, EmbarkNeuro, SynapseBio, BioXcel Therapeutics, and Relmada Therapeutics; he has served on scientific advisory boards ANeuroTech (a division of Anima BV), Brain and Behavior Research Foundation (BBRF), Anxiety and Depression Association of America (ADAA), Skyland Trail, Signant Health, Laureate Institute for Brain Research (LIBR), Inc., Heading Health, Pasithea Therapeutic Corp., and Sage; he holds stock in Seattle Genetics, Corcept Therapeutics Pharmaceuticals Company, EMA Wellness, Precisement Health, Relmada Therapeutics; he serves on the Board of Directors for Gratitude America, ADAA, and Lucy Scientific Discovery, Inc.; and he is named on U.S. patents 6,375,990B1 and 7,148,027B2. Dr. Mayberg has received consulting and intellectual property licensing fees from Abbott Neuromodulation. Dr. Craighead serves on the National Advisory Board for the George West Mental Health Foundation, as a board member of Hugarheill ehf (an Icelandic company dedicated to the prevention of depression), and as a scientific advisory board member for AIM for Mental Health and the Anxiety and Depression Association of America; he is supported by the Mary and John Brock Foundation, the Pitts Foundation, and the Fuqua family foundations; and he receives book royalties from John Wiley.
